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We have identified a gene by microarray analysis that is located on chromosome 6 (c6orf32), whose expression is increased during human fetal
myoblast differentiation. The protein encoded by c6orf32 is expressed both in myogenic and non-myogenic primary cells isolated from 18-week
old human fetal skeletal muscle. Immunofluorescent staining indicated that C6ORF32 localizes to the cellular cytoskeleton and filopodia, and
often displays polarized expression within the cell. mRNA knockdown experiments in the C2C12 murine myoblast cell line demonstrated that
cells lacking c6orf32 exhibit a myogenic differentiation defect, characterized by a decrease in the expression of myogenin and myosin heavy chain
(MHC) proteins, whereas MyoD1 was unaltered. In contrast, overexpression of c6orf32 in C2C12 or HEK293 cells (a non-muscle cell line)
promoted formation of long membrane protrusions (filopodia). Analysis of serial deletion mutants demonstrated that amino acids 55–113 of
C6ORF32 are likely involved in filopodia formation. These results indicate that C6ORF32 is a novel protein likely to play multiple functions,
including promoting myogenic cell differentiation, cytoskeletal rearrangement and filopodia formation.
© 2006 Elsevier Inc. All rights reserved.Keywords: Myoblast; Differentiation; Filopodia; c6orf32 (gene); C6ORF32 (protein); C2C12Introduction
Mononuclear muscle progenitors can be efficiently propa-
gated ex vivo and induced to differentiate to form multinucleated
myotubes (Yablonka-Reuveni, 2004). These processes are
tightly regulated and require the expression of specific proteins
at precise times. Many of the fundamental regulators that
orchestrate myogenic differentiation have been elucidated and
include the myogenic transcription factorsMyoD1, Myf5, MRF4
and myogenin (Charge and Rudnicki, 2004; Berkes and
Tapscott, 2005). Many of these events are recapitulated in vivo
in response to exercise-induced damage or after muscle trauma
(Shi and Garry, 2006). For instance, muscle regeneration is
mediated by the activation of satellite cells, which are also
defined as tissue-specific stem cells (Wagers and Conboy, 2005).
Satellite cells proliferate after acute muscle injury prior to
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doi:10.1016/j.ydbio.2006.11.002fusion to form new myofibers and restore muscle activity. This
process is reminiscent of the events that occur during muscle
development in embryogenesis (Pownall et al., 2002; Parker et
al., 2003). Thus, the mechanisms involved in muscle cell
differentiation that lead to myofiber formation can be dissected
using both in vitro and in vivo models.
Understanding these mechanisms may have broader clinical
implication, as it could highlight new cues on how to improve
the efficacy of cell transplantation as a potential therapy for a
variety of muscle diseases. Some of the key proteins involved in
muscle cell differentiation and myofiber formation are relatively
well studied in Drosophila (Abmayr and Kocherlakota, 2006;
Abmayr et al., 2003; Taylor, 2003; Chen and Olson, 2004). In
this model system, transmembrane proteins such as Dumb-
founded (Duf) and Roughest (Rst) expressed in founder cells,
and Sticks and stones (Sns), expressed in fusion-competent
cells, are involved in the recognition steps during muscle
formation (Bour et al., 2000; Ruiz-Gomez et al., 2000;
Strunkelnberg et al., 2001). Cells lacking both Duf and Rst do
not fuse, while overexpression of either gene can attract fusion-
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2004). When fusion-competent cells recognize and contact
founder cells, proteins such as Antisocial, Loner and Myoblast
city transduce signals from the cell surface to the cytoskeleton
(Erickson et al., 1997; Chen and Olson, 2001; Chen et al., 2003;
Rau et al., 2001). One important family of such signal
transduction proteins is the Rho family of guanine nucleotide
exchange factors (GEF) (Bryan et al., 2005a,b). These proteins
are involved in a number of diverse functions, including
cytoskeletal rearrangement, formation of focal adhesions, cell
polarity, cell cycle progression and neurite outgrowth (Etienne-
Manneville and Hall, 2002). In vertebrates, several additional
proteins have been identified as regulators of myogenic
differentiation and syncitial fusion. These include cell surface
proteins such as metalloproteinase/disintegrins (Yagami-Hiro-
masa et al., 1995), IL-4 and mannose receptors (Horsley et al.,
2003; Jansen and Pavlath, 2006), intracellular proteins such as
calpain and nitric oxide (Lee et al., 1994; Balcerzak et al., 1995;
Barnoy et al., 1998; Dulong et al., 2004) and transcription
factors such as Foxo1a (Bois and Grosveld, 2003; Bois et al.,
2005). However, these are likely to represent only a fraction of
the proteins that regulate these complex biological processes.
To identify novel candidate genes, we performed microarray
analyses on human fetal primary muscle cultures harvested at
three distinct stages of myogenic differentiation: myoblasts,
early myotubes and late myotubes (Cerletti et al., 2006). It was
found that c6orf32 is one of the genes upregulated early during
muscle cell differentiation, when myotubes have a maximum of
5 nuclei. High levels of c6orf32 mRNA are maintained when
myotubes are larger in size (up to 15 myonuclei) (Cerletti et al.,
2006). C6orf32 is also known as pl48, or diff48 (NCBI,
AceView). Pl48 (a short isoform of c6orf32) was isolated by
subtractive hybridization between cDNAs derived from undif-
ferentiated human cytotrophoblast and differentiating cytotro-
phoblast (Dakour et al., 1997). The level of pl48 mRNA
increases during cytotrophoblast differentiation and it has been
suggested that it may play a role in the formation of non-mitotic
multinucleated syncytium during placental differentiation
(Dakour et al., 1997). PL48 contains a number of putative
functional motifs, including a potential transmembrane domain,
myristylation signals, and several phosphorylation sites,
suggesting multiple regulatory functions; however, none of
these putative motifs have been further studied or tested for
function (Dakour et al., 1997).
To gain insight on the function of c6orf32 (a longer isoform
of pl48) in muscle cells, we first confirmed that this protein was
expressed upon human fetal myoblast differentiation, when
muscle cells become confluent and begin to fuse. The protein
was localized at the cell membrane, in the cytoplasm and also in
cellular filopodia associated with cytoskeletal proteins. We then
studied the consequences of modulating the expression of
c6orf32 in vitro, both via mRNA knockdown and via over-
expression in muscle cells. mRNA knockdown experiments in
C2C12 murine myoblasts demonstrated that reduced c6orf32
expression significantly decreased fusion of mononuclear cells
into multinucleated myotubes. This apparent fusion defect
appears to be a secondary effect due to altered myoblastdifferentiation, as demonstrated by reduced expression of
myogenin. In contrast, over-expression of c6orf32 promotes
formation of filopodia both in muscle and in non-muscle cells.
Deletion mutant studies indicated that amino acids 55–113 of
C6ORF32 are likely involved in the formation of filopodia.
Together, these results suggest that just like described for GEFs,
C6ORF32 may play multiple roles during muscle cell
differentiation by mediating filopodia formation, cytoskeletal
rearrangement, and by influencing either directly or indirectly
the progression of myogenic differentiation.
Materials and methods
Cloning of c6orf32
C6orf32 cDNA was amplified by RT-PCR from total RNA of human
primary fetal muscle cells harvested after 5 days in differentiation medium. The
primer set used for amplifying the c6orf32 cDNAwas as follows: c6orf32 ISO1,
ATGTTGGTAGGATCCCAGTC (forward) and CAGCTGTTAGGCAGT-
TAACCTGTA (reverse); c6orf32 ISO2, ATGTTGGTAGGATCCCAGTC
(forward) and CTACTTTTTTAGAATATCATC (reverse). Amplified c6orf32
cDNA was inserted into pCR4-TOPO and sequenced. To obtain a V5-tagged
C6ORF32 protein, c6orf32 was PCR amplified and inserted into pCDNA3.1/
V5-His-TOPO (Invitrogen). The plasmids encoding the N-terminal and C-
terminal Flag-tagged C6ORF32 were generated by PCR amplification using a
primer encoding the flag sequence (GACTACAAAGACGATGACGA-
CAAG). The plasmids encoding truncated C6ORF32 proteins were generated
by PCR amplification of the relevant regions and were verified by sequence
analyses.
Cell culture
HEK293 cells were maintained in DMEM supplemented with 10% (v/v)
fetal calf serum, penicillin/streptomycin (50 units/ml) and L-glutamine (2 mM).
Human fetal primary myoblasts were isolated and maintained as previously
described (Pavlath and Gussoni, 2005). Murine C2C12 cells were maintained in
DMEM containing 20% (v/v) fetal calf serum supplemented with penicillin,
streptomycin and L-glutamine. For HEK293 cells, the indicated plasmids were
transfected using lipofectamine 2000™ (Invitrogen) (2 μl lipofectamine/μg
DNA) in suspension. The culture medium was replaced in the dishes 6–8 h after
transfection. Approximately 20–24 h post-transfection cells were immunos-
tained or visualized by phase microscopy. For C2C12 cells, the indicated
plasmids were transfected using the Amaxa electroporation system for C2C12
cells (Nucleofector V solution, Amaxa). The culture medium was replaced in the
dishes 10–14 h after transfection. Approximately 20 h post-transfection cells
were immunostained.
Immunostaining
HEK293 or C2C12 cells were fixed in cold methanol for 2 min, blocked with
PBS containing 1% BSA for 1 h and incubated with rabbit anti-V5 antibody
(1:500, Sigma) or with rabbit anti-Flag antibody (1:100, Sigma) overnight at
4°C. Primary human fetal muscle cells were fixed in 4% paraformaldehyde
containing 0.3% Triton X-100 for 10 min, blocked with PBS containing 1%
BSA for 1 h and incubated overnight at 4°C with one of the following primary
antibodies: anti-desmin 1:500 (Epitomics), anti-C6ORF32 1:400 (Abnova),
anti-MyoD 1:200 (BD Pharmingen), anti-myogenin 1:100 (DakoCytomation),
anti-myosin heavy chain (MF20, 1:30, Developmental Studies Hybridoma
Bank, University of Iowa) and anti-dystrophin 1:1500 (Byers et al., 1993; Lidov
et al., 1993). After three washes with PBS, cells were incubated with the
appropriate secondary antibody conjugated with FITC, Alexa 488 or
Rhodamine. For co-immunostaining of phalloidin with C6ORF32, phalloidin-
Alexa 568 (Invitrogen) was reconstituted as per manufacturer's instruction,
diluted 1:50 in PBS and added together with the secondary antibody. Cells were
visualized using a Nikon Eclipse E-1000 microscope, photographed using a
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version 3.1.5 (Improvision). For the C6ORF32 Flag-tagged overexpression and
deletion mutant analyses, cells were visualized using a Nikon Eclipse TE2000-
S, photographed using a Nikon 7.4 Slider camera, and images were acquired
using Spot software version 4.1.1 (Diagnostic Instruments).
Quantitative RT-PCR
Total RNA was isolated from human fetal tissue using the Qiagen RNA
isolation kit, and cDNA was reversed-transcribed using the Superscript RT kit
(Invitrogen), according to the manufacturer's instructions. PCR primer
sequences for human c6orf32 were selected as follows: TTTCTGCCCCTGA-
TAGTTGG (forward) and CATGTCCTCCACGTCAAATG (reverse), which
amplify a 207 bp product. PCR amplification was performed using the SYBR
Green PCR master mix Kit (Applied Biosystems) for 46 cycles at 95°C for 15 s
and 60°C for 1 min. The end product of the RT-PCR reactions were
electrophoresed on 1.7% agarose gel and DNA was visualized by ethidium
bromide staining. The PCR product was confirmed by sequence analysis and
using the Sequence Detector v1.7a software. All quantitations were normalized
to the endogenous control gapdh, which was amplified under the same
conditions in separate tubes. Human gapdh primer sequences are as follow:
GAAGGTGAAGGTCGGAGTC (forward) and GAAGATGGTGATGG-
GATTTC (reverse).
Immunoblotting
Cells were lysed in 50 mM Tris–Cl, pH 7.5, 150 mM NaCl, 1% Triton X-
100, 1× protease inhibitor cocktail (Invitrogen). Total proteins were separated on
4–12% polyacrylamide NuPAGE Bis–Tris precast gels (Invitrogen) and blotted
on nitrocellulose membrane (Invitrogen). The membrane was incubated with
anti-C6ORF32 antibody (1:1000 dilution, Abnova, Taiwan), followed by
peroxidase conjugated affinity purified goat anti-mouse IgG (Vector). Signals
were detected using the ECL kit (Amersham).
In vitro RNA interference
Retroviral constructs encoding small interfering RNAs targeting mouse
c6orf32 (accession number AL513014) were obtained or synthesized according
to manufacturer's instructions (BD Biosciences). To generate hairpin siRNA,
67-bp oligonucleotides complementary to different target sequences of mouse
c6orf32 cDNA were synthesized (Dharmacon) (536: TGACCTAGACAAG-
CAAATT; 612: CTCTATGAAGCCTATTGTA) and inserted into the pSIREN-
retroQ vector (BD Biosciences).
Retroviral vector stocks were produced by transient transfection using
the ProFection Mammalian Transfection Systems-calcium phosphate kit
(Promega). Briefly, 4 μg of VSV-G (envelope) and 7 μg of appropriate
vector were transfected by calcium phosphate onto 293GP cells at 70%
confluency in 6 cm dishes overnight. The following morning the cell
medium was replaced with 2.5 ml of medium and the viral supernatants
harvested 24–30 h later.
For retroviral infection of C2C12, cells were plated into 12-well plates and
infected overnight with 4 μg/ml of polybrene and 300 μl of viral supernatant.
Each infection was performed in duplicate and the following day the culture
medium was replaced. Proliferation medium was switched to low serum (2%
horse serum) differentiation medium when cells were approximately 90%
confluent. Myotube formation was examined on the fourth day after addition
of differentiation medium. The fusion index (FI) was calculated by dividing
the number of nuclei contained within myotubes by the total number of nuclei
in a given field. A total of 6 randomly chosen fields (3 for each replica
infection) were visually counted per each sample. To quantify the level of
c6orf32 gene expression in C2C12 cells, real-time quantitative RT-PCR was
performed on C2C12 RNA isolated from each culture using the SYBR Green
PCR master mix Kit (Applied Biosystems). PCR primers for mouse c6orf32
GGGCTTGATGAGTACCTGGA (forward), and GAAGGCTTGCTT-
CATTTTGC (reverse) and for gapdh as an internal control: gapdh
AACTTTGGCATTGTGGAAGG (forward), and ACACATTGGGGGTAG-
GAACA (reverse). PCR amplification was performed for 55 cycles at 95°C
for 15 s and 60°C for 1 min.Results
Expression of c6orf32 mRNA during differentiation of human
fetal myoblasts
Microarray studies interrogating genes regulated during
differentiation and fusion of human fetal myoblasts indicated
that the level of c6orf32 expression is increased during the
early steps of these processes (Cerletti et al., 2006).
Quantitative real-time PCR was performed to confirm these
results. Total RNA was isolated from human fetal muscle cells
at each stage of differentiation (Fig. 1A). We have defined
myoblasts as mononuclear cells, early myotubes as cells
containing between 2 and 5 myonuclei, and late myotubes as
cells containing up to 15 myonuclei. Real-time quantitative RT-
PCR demonstrated that expression of c6orf32 mRNA increased
approximately 16-fold in both early and late myotubes (Fig.
1B, b, c) compared to the levels detected in mononuclear cells
(Fig. 1B, a). Fig. 1C illustrates the PCR products at ‘plateau’
levels, indicating that the primers specifically amplified one
product, which was confirmed by sequence analysis to be
c6orf32.
Localization of native C6ORF32 during human fetal myoblast
fusion
In cultures of primary human fetal skeletal muscle cells
maintained under proliferation conditions, no expression of
C6ORF32 was detected (data not shown). When cells were
allowed to make contact and cultures were switched to
differentation medium, C6ORF32 expression was detected at
the cell membrane and it also appeared associated with the cell
cytoskeleton, often localized to one side of the cell (Figs. 1D–F,
arrows). In rare cells undergoing mitosis, C6ORF32 localized to
the cytoplasm (Figs. 1G, H open arrowhead) and spread to
filopodia-like protrusions that resembled cellular anchorage
points (Fig. 1H, arrow). C6ORF32 protein was also detected in
long cellular filopodia (Figs. 1I–M). Simulataneous detection of
C6ORF32 expression with F-actin suggested co-localization of
these proteins (Figs. 1N–Q, arrows), although C6ORF32 also
appeared present in cytoplasmic regions negative for F-actin
expression (Figs. 1O, Q). To investigate whether cells positive
for C6ORF32 in human fetal primary muscle cultures were
myogenic, co-immunostaining of C6ORF32 and desmin or
dystrophin were performed during a time-course differentiation
study (Fig. 2). In mononuclear cells prior to fusion, co-
localization of C6ORF32 protein with desmin demonstrated
that C6ORF32 is expressed both in myogenic (Figs. 2A, B) and
non-myogenic cells (Fig. 2C). Cells expressing C6ORF32 were
mononuclear and often located adjacent to multinucleated
myotubes, which were positive for dystrophin (Figs. 2D–H).
Co-expression of dystrophin and C6ORF32 was also noted in
cells very closely located to one another that may have been
undergoing fusion (Figs. 2I, J, arrowheads). To estimate the
percentage of C6ORF32-positive cells at different timepoints
during myogenic differentiation, the number of cells positive for
C6ORF32 over the total number of nuclei in 5 random
Fig. 1. C6ORF32 mRNA is upregulated upon differentiation of human fetal myoblasts. (A) Phase contrast images of cultured human fetal myoblasts harvested for RT-
PCR analyses. (B) Quantitative RT-PCR graph illustrating increased amounts of C6ORF32 mRNA during human fetal myoblast differentiation. a, myoblasts; b, early
myotubes; c, late myotubes. Each PCR reaction was performed in duplicate and GAPDH was used as an internal control. (C) The end products (plateau levels) of the
RT-PCR reactions were run on an agarose gel, purified and sequenced to confirm their specificity. (D–M) Immunofluorescence detection of C6ORF32 protein (green)
in differentiating human primary fetal myoblast cultures. Expression was detected in the cytoskeleton (E–G), rare cells undergoing mitosis (G, H open arrowheads) and
in cellular filopodia (I–M, arrows). (N–Q) Localization of C6ORF32 (green) and phalloidin (red, which binds to F-actin). C6ORF32 appears to localize with F-actin
(yellow, arrows), but it is also expressed in the cytoplasm. Nuclei are counterstained in blue with DAPI.
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days −1, +3 and +5 (day 0 is when differentiation medium was
added to the cultures). C6ORF32-positive cells were approxi-mately 5% at day −1 (70% of which stained positive for
desmin), and increased to 18.6% at day 3 and to 43.3% at day 5
of differentiation.
Fig. 2. Expression of C6ORF32 protein during human fetal myoblast fusion.
(A–C) At day −1, cells were co-stained for desmin (red) and C6ORF32 (green).
Nuclei are stained in blue with DAPI. C6ORF32 is detected both in myogenic
(A, B) and non-myogenic cells (C, open arrowhead). (D–J) Human fetal
myoblasts were induced to differentiate in low serum medium (added at day 0)
for 5 days. Cultures were co-stained for dystrophin (red) and C6ORF32 (green).
C6ORF32-positive mononuclear cells were adjacent to dystrophin-positive
myotubes (D–H, arrows). (I–J) Co-detection of dystrophin and C6ORF32 was
seen is rare cells that appeared to be undergoing fusion (open arrowheads).
Fig. 3. Multiple isoforms of C6ORF32 protein are upregulated during human
muscle cell differentiation. (A) Western blot using mouse anti-C6ORF32
monoclonal antibody. Lane 1, 20 μg of cell lysate from mock-transfected
HEK293 cells; lane 2, 10 μg of cell lysate from HEK293 cells transfected with
C6ORF32 ISO2-expressing plasmid; lane 3, 45 μg of cell lysate from human
primary myoblast cells 2 days prior to fusion (day −2); lane 4, 45 μg of cell
lysate from human primary myoblast cells just before switching medium into
differentiation medium (day 0); Lane 5, 45 μg of cell lysate from human primary
myoblast cells 1 day after switching medium into differentiation medium (day
+1). Black arrowheads point at putative C6ORF32 isoforms that are upregulated
during fusion, the white arrowhead points to a band that does not increase during
differentiation. (B) Schematics of C6ORF32 ISO1 and ISO2 proteins compared
to the known AB002384 and PL48. C6ORF32 ISO2 is a truncated form of
C6ORF32 ISO1 protein.
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myoblasts
C6orf32 is an open reading frame putatively encoding 12
alternatively spliced forms (NCBI, AceView). To analyze
whether multiple isoforms of this protein are expressed in
human fetal muscle cells under differentiation in vitro, western
blot analysis was performed (Fig. 3A). Several isoforms of
C6ORF32 protein were detected in human fetal muscle cellsduring fusion, and the amount of some of these isoforms
increased during differentiation (Fig. 3A, black arrowheads).
Two known alternatively spliced forms of c6orf32 were
amplified by RT-PCR from human fetal muscle cells (Iso 1 and
Iso 2). Primers were designed according to the nucleotide
sequences of AB002384 (1068 aa), which encodes the longest
known isoform, and NM_015864 (Iso 2, 591 aa). As shown in
Fig. 3A, Iso 1 (1018 aa), an isoform known to be expressed in
brain (NCBI, AceView), and Iso 2 are expressed during
differentiation of human fetal primary myoblasts. C6ORF32
Iso 2 (591 aa) is also present in muscle and is 50 amino acids
longer at its N-terminus than PL48, which is expressed in
placenta (Fig. 3B) (Dakour et al., 1997).
Effect of c6orf32 mRNA knockdown during muscle cell
differentiation
To investigate the function of c6orf32 during myoblast
differentiation, its expression was inhibited via in vitro RNA
silencing (RNAi). Similarly to our findings in primary human
fetal muscle cells, the expression of mouse c6orf32 mRNA in
C2C12 cells increases approximately 6-fold after 4 days in
differentiation medium (data not shown). Two small interfering
RNAs (siRNA 536, 612) were generated using oligonucleotides
specific to the mouse c6orf32 sequence and tested on the mouse
myogenic cell line C2C12, while a retrovirus encoding the lacZ
Fig. 4. mRNA knockdown of c6orf32 in C2C12 cells infected with retroviruses containing two distinct siRNA oligos. (A) Schematic representation of RNA
interference experiment. (B) Quantitative real-time RT-PCR was performed to estimate the amount of c6orf32 mRNA after treatment with each siRNA, which was
approximately 20% of normal levels. (C) mRNA knockdown of c6orf32 slows myotube formation in C2C12 cells, as represented by phase contrast and by
immunostaining of the cultures for myosin heavy chain (MHC, green). Note that the cultures with decreased c6orf32 mRNA expression have also low numbers of
MHC-positive cells. (D) Fusion index of C2C12 cultures treated with control or siRNA for c6orf32. Both oligo 536 and 612 exhibited significant decrease in myotube
formation compared to control cultures.
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cells were infected with the retroviruses 2 days before switching
the cultures from proliferation to differentiation medium (Fig.
4A). C6orf32 mRNA expression was analyzed at day 0, while
cell fusion was assessed after 4 days in differentiation medium.
The efficacy of each siRNA to down-regulate c6orf32 mRNA
expression was assessed via quantitative real-time RT-PCR
(Fig. 4B). PCR amplifications demonstrated that siRNA 536
and 612 down-regulate mouse c6orf32 mRNA to 23% and 19%
of normal levels, respectively (Fig. 4B). Gapdh expression in
each cell line was also measured as an internal control for non-
specific inhibition of the siRNAs, which was not detected.
C2C12 cultures infected with retroviruses containing the
siRNAs or the control lacZ gene were also assessed for cell
fusion and expression of the myogenic differentiation marker
myosin heavy chain (MHC) (Fig. 4C). Cells infected with
c6orf32 siRNAs showed decreased fusion compared to the
control culture infected with lacZ (Fig. 4C). In particular,
C2C12 cells infected with the retrovirus encoding siRNA 536
exhibited severe reduction of myotube formation (Fig. 4C). The
fusion index was determined by counting the number of nucleiFig. 5. Expression of MyoD1 and myogenin in C2C12 cells after knockdown o
immunostained with MyoD1 or myogenin (green) and nuclei were counterstained w
that the percentage of MyoD1+ cells is not affected after treatment with siRNA oligo
myogenic differentiation marker myogenin is significantly decreased in cultures witwithin myotubes, divided by the total number of nuclei. These
numbers were obtained for 6 random fields in each sample, and
numbers were obtained from 4 independent experiments (Fig.
4D). Results demonstrated that siRNA 536 and 612 signifi-
cantly decreased myotube formation compared to control
retrovirus-infected cells (Fig. 4D).
To determine whether the observed decreased fusion of
C2C12 could be a secondary effect due to a defect in the
progression of muscle cell differentiation, expression of
MyoD1, a master regulator that is expressed in proliferating
muscle cells (Lassar et al., 1989) and myogenin, an early marker
of myogenic differentiation (Wright et al., 1989) were assessed
by immunofluorescence in the cultures infected with retro-
viruses containing siRNA oligo 536 and 612 (Fig. 5A). After
4 days in differentiation medium, the expression of MyoD1 in
C2C12 cells treated with c6orf32 siRNA 536 and 612 was not
significantly different from control cultures infected with LacZ
(Fig. 5A). In contrast, expression of myogenin was significantly
decreased in C2C12 cells infected with siRNA 536 and 612,
suggesting that myogenic differentiation was affected by
reduced expression of c6orf32 (Figs. 5A, B). These resultsf c6orf32 mRNA. (A) C2C12 cells at day 4 in differentiation medium were
ith DAPI (blue). (B) Quantitation of MyoD1+ and myogenin+ cells demonstrate
s 536 or 612 compared to the control culture, while the expression of the early
h reduced c6orf32 mRNA expression.
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myogenic differentiation and the decreased muscle cell fusion
observed after RNA knockdown is a secondary effect due to
impaired or slowed differentiation.
Over-expression and localization of tagged C6ORF32 in
muscle and non-muscle cells
Inhibition of expression of c6orf32 mRNA in vitro in
C2C12 cells demonstrated that down-regulation of this gene
results in decreased myogenic differentiation. To gain insight on
the putative role of this protein, two c6orf32 constructs were
over-expressed in the myoblast cell line C2C12 and in theFig. 6. Over-expression of C6ORF32 in murine C2C12 (B) and HEK293 cells (C). (
human cytomegalovirus enhancer/promoter and pA is the BGH polyadenylation sign
ISO2-Flag was detected using an anti-flag antibody (green) and nuclei were counter
transfected C2C12 (B) and HEK293 cells (C), but not with the control plasmid enchuman-derived kidney cell line, HEK293 (Fig. 6). In the
constructs, a Flag-tag was placed at either the N- or the C-
terminus of c6orf32-ISO2 by inserting the appropriate synthetic
oligonucleotide into the primer sequence when amplifying
c6orf32-ISO2 by PCR (Fig. 6A). Both constructs were
sequenced to confirm the changes yielded to an in-frame
product. C2C12 cells (Fig. 6B) and HEK293 cells (Fig. 6C)
were transfected with the plasmids in the presence of
lipofectamine. Approximately 20–24 h post-transfection cells
were stained with an anti-Flag antibody and protein expression
was detected in both the cytoplasm and filopodia of transfected
cells (Figs. 6B, C, white arrows). Phase contrast images
demonstrated that cells transfected with c6orf32-ISO2 plasmidsA) Schematic representation of the constructs used for transfection. CMV is the
al. Protein expression in cells transfected with pFlag-c6orf32-ISO2 or pc6orf32-
stained with DAPI (blue). Images demonstrate the presence of long filopodia in
oding for GFP.
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C2C12 cells transfected with GFP (Figs. 6B, C). These results
were also seen in C2C12 cells transfected with c6orf32-ISO1
(data not shown). Therefore, overexpression of c6orf32 in both
muscle and non-muscle cells induces formation of filopodia and
supports our initial findings in human muscle primary cells,
where C6ORF32 was detected in the cytoplasm and cellular
filopodia (Fig. 1).
To determine the domain of C6ORF32 that promotes the
formation of filopodia, serial in frame deletion mutants of
c6orf32 tagged with V5 were constructed and transfected intoFig. 7. The N-terminus domain of C6ORF32 (aa 55–113) is important for formatio
plasmid and immunostained with anti-V5 polyclonal antibody (green), cell nuclei we
decreased number of filopodia. (B) Schematic of deletion mutants constructed to deC2C12 cells (Fig. 7B). Cells were examined 20 h after
transfection by immunostaining with a rabbit polyclonal anti-
V5 antibody (Fig. 7A). Results demonstrated that the N-
terminal region (55–113aa) is important for filopodia formation
(Fig. 7A, Table 1). The percentage of cells with filopodia in
C2C12 cells transfected with plasmids encoding mutant forms
of c6orf32 was quantified (Table 1). Transfection with plasmids
deleting 53 amino acids from the N-terminus (Fig. 7A, N-D54)
or deleting 110 amino acids from the C-terminus (Fig. 7A, C-
D110) did not cause a loss of filopodia formation. However,
after transfection with plasmid D113, in which 113 amino acidsn of cellular filopodia. (A) C2C12 cells were transfected with each designated
re counterstained with DAPI (blue). Cells transfected with N-D113-V5 exhibited
termine the region of C6ORF32 responsible for the formation of filopodia.
Table 1
Percentage of C2C12 cells with filopodia after transfection of C6ORF32
deletion mutants
Plasmid Total (n) +Filopodia (n) −Filopodia (n) %Filopodia
pC6ORF32 ISO2 605 295 310 48
N-D54 131 62 69 47
N-D113 185 20 165 11
C-D110 398 192 206 48
C2C12 cells were transfected with each plasmid as specified and immunostained
with polyclonal anti-V5 antibody 20 h after transfection. The overall transfection
efficiency for mutants D54 and D113 was lower than in cells transfected with
C6ORF32-Iso2 and C-D110. The percentage of filopodia was calculated by
dividing the number of transfected cells exhibiting filopodia (+filopodia) by the
total number of C2C12 transfected cells.
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percentage of transfected cells exhibiting filopodia decreased
from 48% to 10% (Fig. 7A, Table 1). Similar results were also
obtained using HEK293 cells (data not shown). These results
suggest that amino acids 55–113 in C6ORF32 are likely
involved in the formation of cell filopodia.
Discussion
Cellular differentiation and fusion are essential steps in
muscle development. During these processes, myoblasts
undergo changes in expression of myogenic regulatory factors
prior to recognizing, adhering and fusing with each other to
form myotubes. Several proteins have been identified that are
involved in vertebrate muscle cell differentiation and fusion
(Lee et al., 1994; Balcerzak et al., 1995; Yagami-Hiromasa et
al., 1995; Barnoy et al., 1998; Gorza and Vitadello, 2000; Bois
and Grosveld, 2003; Horsley et al., 2003; Dulong et al., 2004).
However, despite these reports, detailed understanding of these
processes is unknown; therefore, it is likely that several key
proteins have yet to be identified. Using microarrays, we sought
for genes regulated during fusion of human fetal myoblast in
vitro (Cerletti et al., 2006). Among the ones that appeared to
increase in expression during ‘early’ fusion (2–5 myonuclei)
was a gene named c6orf32. Expression of c6orf32 was
confirmed to be upregulated during human myoblast differ-
entiation at both the mRNA and protein levels. Localization of
C6ORF32 by immunofluorescence in primary human myoblast
cultures demonstrated this protein localizes to the cell
membrane and in filopodia-like structures. C6ORF32 is
expressed in mononuclear cells, not in myotubes, upon
induction of differentiation and cellular fusion. Co-staining
with the myoblast-specific marker desmin indicated that both
myogenic and non-myogenic cells within human primary
muscle cultures express this protein. Mononuclear cells
expressing C6ORF32 often displayed localization of the protein
to one side of the membrane, adjacent to a multinucleated
myotube.
To elucidate the function of C6ORF32 during muscle cell
differentiation, down-regulation and over-expression of this
protein were studied in vitro. RNAi experiments performed on
the murine muscle cell line C2C12 demonstrated that down-
regulation of C6ORF32 mRNA caused a significant decrease inmyoblast fusion. To investigate the step at which C6ORF32
downregulation affects myoblast fusion, cultures of C6ORF32
RNA knockdown were analyzed for expression of myogenic
markers, such as MyoD, myogenin and MHC. Results indicated
that down-regulation of c6orf32 correlated with reduced levels
of myogenin and MHC, both markers of myogenic differentia-
tion, while the levels of MyoD1, expressed in proliferating
myoblasts, were unaltered. These results suggest that impaired
cell fusion due to decreased C6ORF32 expression is likely a
secondary effect due to altered myogenic differentiation.
Over-expression of c6orf32 studies in both muscle and non-
muscle cells showed increased formation of filopodia-like
structures, which supported the localization studies performed
on primary human muscle cells. Short filopodia are commonly
found in motile cells, such as fibroblasts and keratinocytes
(Salas-Vidal and Lomeli, 2004), while longer thin filopodia
have been implicated in crucial morphogenetic events during
development, including muscle development (Tanaka-Mata-
katsu et al., 1996; Jacinto et al., 2000; Fulga and Rorth, 2002;
Ritzenthaler and Chiba, 2003). Filopodia are formed by actin
polymerization, which is regulated by the Rho family of small
guanosine triphosphatase (Rho GTPase) such as RhoA, Rac1
and Cdc42 (Hall, 1998; Miki et al., 1998). Signaling through
Rho GTPase is mediated by the intracellular proteins WASP and
Arp2/3, which result in actin assembly (Snapper et al., 2001). In
Drosophila, it has been reported that many intracellular proteins
involved in myoblast fusion have a role in regulating the actin
cytoskeleton (Chen and Olson, 2005). We therefore speculate
that C6ORF32 may be a protein involved in cytoskeletal
rearrangement during muscle cell differentiation that leads to
cell fusion. In the overexpression studies, we identified that
amino acids 55–113 are necessary to promote formation of
cellular filopodia. Upon overexpression, it was observed that
multiple filopodia were induced in HEK293 or C2C12 cells.
These results suggest that upregulation of C6ORF32 may be in
response to signals that induce cellular movement, including the
migration of myogenic cells towards the site where fusion will
occur.
In conclusion, we have found that C6ORF32 is a previously
unrecognized protein upregulated during human fetal muscle
cell differentiation. Downregulation of its expression in vitro
causes a decrease in differentiation and fusion, while its
upregulation promotes formation of cellular filopodia, sugges-
ting a role of C6ORF32 in the cytoskeletal rearrangement
during fusion of myoblasts into multinucleated myotubes.
Future studies will address whether C6ORF32 is a novel GEF
factor by dissecting its putative multiple roles and by defining
their precise links to myogenic cell differentiation.
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